Kidney regeneration and repair after transplantation by Franquesa, M. (Marcella) et al.
REVIEW CURRENTOPINION Kidney regeneration and repair after transplantationCopyright © Lippincott W
1087-2418  2013 Wolters Kluwera, b, bMarcella Franquesa , Maria Flaquer , Josep M. Cruzado , and
Josep M. Grinyo´bPurpose of review
To briefly show which are the mechanisms and cell types involved in kidney regeneration and describe
some of the therapies currently under study in regenerative medicine for kidney transplantation.
Recent findings
The kidney contains cell progenitors that under specific circumstances have the ability to regenerate specific
structures. Apart from the knowledge gained in the self-regenerative properties of the kidney, new concepts
in regenerative medicine such as organ engineering and the use of mesenchymal stem cell-based therapies
are currently the focus of attention in the field.
Summary
Overall, kidney regeneration is a reality and the knowledge on how to control it will be one of the main
scopes in the present and future.
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Kidney transplantation is the best option for end-
stage renal disease patients. However, this is only
a temporary solution and most of the patients
develop interstitial fibrosis and tubular atrophy
and eventually lose their grafts. A better knowledge
on endogenous healing mechanisms for nonfibrotic
wound healing and new therapies designed
to increase the regenerative potential of the kidney
might mean in a near future a longer graft survival
or even no need for transplantation because of
regeneration of native kidney.
In the context of kidney transplantation, the
possibility to obtain biopsies regularly could provide
a window of opportunity to detect stable grafts with
initial signs of fibrosis, which could be used to foster
regeneration before the onset of complete damage.
Until now, transplantation research has focused
on the impact of the immunosuppressive drugs
on the graft survival; however, these drugs
might have a negative impact on the potential
regeneration ability of the graft [1–3].Univeristari de Bellvitge-IDIBELL, Barcelona, Spain
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The kidney has been classically considered unable
to regenerate, in comparison with other organs such
as the liver. Advances in developmental biology andilliams & Wilkins. Unaut
Health | Lippincott Williams & Wilkin the knowledge of the balance between regener-
ation and fibrosis have brought major advances in
the last years.Adult kidney stem cell niches
When an adult tissue is damaged, the cell renewal
process is crucial for its maintenance and, in certain
organs, this is achieved by the presence of stem cells.
These stem cell populations are housed in an in-vivo
milieu, named a niche, which regulates stem cell
survival, self-renewal, and differentiation. Stem cell
niches are present in many adult organs and tissues
[4]. In a normal environment, stem cells remain
quiescent into the niche during long periods of
time until they are activated by the requirement
of new cells to maintain the tissue or because of
tissue damage. When an insult happens, stem cells
might be activated, exit the niche, proliferate, andhorized reproduction of this article is prohibited.
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KEY POINTS
 The kidney has intrinsic ability to regenerate after
an injury.
 Several populations of stem cells with regenerative
potential have been identified in the renal parenchyma.
 Regenerative medicine and organ engineering hold the
potential to be the best alternatives to current treatments
in transplantation.
 Mesenchymal stem cells and their derived microvesicles
have been shown to protect from developing
chronic injury.
 Other therapies such as hepatocyte growth factor or
microvasculature regeneration enhances have already
proven the regenerative potential in animal models.
Organogenesis and organ regeneration and repair after transplantationdifferentiate into the needed cell types to replace the
cell lost.
The kidney has a very complex structure and is
composed of more than 20 cell types that function
as a tissue unit rather than as individual cells,
making harder its regeneration. These factors make
it difficult to find a single renal stem cell able to
differentiate into each renal cell type. Overcoming
all these complications, some stem cell niches
have been proposed in different renal compart-
ments: the renal corpuscle, the nephron tubule,
and the renal papilla.
Glomerular populations (the renal
corpuscle)
Sagrinati et al. [5] identified, in human adult
kidneys, a subset of parietal epithelial cells (PECs)
in the Bowman’s capsule that exhibit coexpression
of the stem cell markers (CD24þCD133þ). CD24 is
a surface molecule expressed in the developing
human fetal kidneys [6] and it has been used to
identify different types of human stem cells [7].
CD133 is also expressed in human fetal kidney
(by around 50% of the cells) and only in 0.5–3%
of the adult human kidney [8].
This CD24þCD133þ PEC population reveals
self-renewal potential and a high cloning efficiency.
The localization of this CD24þCD133þ population
is suitable for both podocyte and tubule regener-
ation. The infusion of CD24þ and CD133þ cells
in SCID mice with acute renal failure resulted in
the regeneration of tubular structures ameliorating
the morphologic and functional kidney damage. A
transitional cell population (CD24þCD133þPDXþ)
shares the features of either renal progenitors or
podocytes and localizes between the urinary polepyright © Lippincott Williams & Wilkins. Unautho
192 www.co-transplantation.comand the vascular pole [7]. More recently, Angelotti
et al. [9
&&
] have demonstrated that this CD24þ
CD133þ progenitor population can be distinguished
in distinct subpopulations from normal human
kidneys based on the surface expression of vascular
cell adhesion molecule 1 (CD106). Thus, it has been
described in two subpopulations: CD24þCD133þ
CD106þ which is localized at the urinary pole and
CD24þCD133þCD106 localized in the proximal
tubule as well as in the distal convoluted tubule.
The CD24þCD133þCD106þ subpopulation exhibits
a high proliferative rate and can differentiate toward
the podocyte as well as the tubular lineage. By
contrast, the CD24þCD133þCD106 subpopulation
shows a lower proliferative capacity and solely
differentiates into the tubular lineage. Both sub-
populations, when injected into SCID mice with
acute tubular injury, were able to engraft within
the kidney, generate tubular cells, and improve
renal function.
Bruno et al. [10
&&
] identified another glomerular
population with stem cell features. They found that
human glomeruli deprived of the Bowman’s
capsule contain a population of CD133CD146þ
cells that coexpress the typical mesenchymal stem
cell markers (such as CD29, CD105, and CD73) and
renal-specific stem cell markers (such as CD24 and
Pax2). This population exhibits in-vitro self-renewal
capability, clonogenicity, and multipotency. More-
over, when these cells are cultured in the appropri-
ate culture conditions, they are able to differentiate
into endothelial cells, epithelial cells expressing
podocyte markers, and mesangial cells.
Tubular populations
The tubules of the kidney display a remarkable
capacity for self-renewal on damage. Whether
this regeneration is mediated by dedifferentiating
surviving cells or stem cells has not been completely
settled. On one hand, Humphreys et al. [11]
described that nonlethally injured cells repopulate
the kidney epithelium after injury in the absence of
any specialized progenitor cell population. On the
other hand, Lindgren et al. [12] detected a pro-
genitor cell population in human kidney scattered
through the proximal tubules which expressed
the markers previously described for PECs, CD24
and CD133, and displays mixed features of renal
progenitors and tubular cells. These tubular progen-
itors may proliferate and differentiate after tubular
injury to replace dead cells. Moreover, it is well
known that CD24þCD133þ (either PECs or tubular
populations) express cytokeratin 7, cytokeratin 19,
BLC2 (antiapoptotic gene), MYOF (regeneration-
promoting molecule), and vimentin. Although thisrized reproduction of this article is prohibited.
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fication of novel markers that may allow distinction
between CD24þCD133þ renal progenitors of
Bowman’s capsule and CD24þCD133þ tubular cells
is still required, as has been performed for podocytes
(CD24þCD133þ PDX vs. CD24þCD133þPDXþ).
Otherwise, according to findings by Patschan
and Oliver, in which they described the migration
of nestin-positive cells following acute kidney injury
[13,14], an overexpression of nestin in proximal
tubules that may participate in the cell migration
during renal repair has been recently observed [15].
The renal papilla
Oliver et al. determined, some years ago, another
niche for adult kidney stem cells [14]. These authors
detected a cell population in the renal papilla, which
had a slow cycling rate. It was observed that during
the repair phase of transient renal ischemia, these
cells entered the cell cycle. More recently, these
authors described that the SDF-1/CXCR4 axis is
a critical regulator of papillary label-retaining cells
activation following transient kidney injury and
during organ repair [16].REGENERATIVE MEDICINE
Cell therapies and organ engineering are two major
lines of research in kidney regenerative medicine
(Fig. 1). Advances in the field are fast growing and
changing concepts.Organ engineering
One of the research lines that has attracted much of
the attention in the last years in kidney regeneration
is the use of decellularized organs. BioengineeringCopyright © Lippincott Williams & Wilkins. Unaut
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1087-2418  2013 Wolters Kluwer Health | Lippincott Williams & Wilkcustom-made organs, in which the cellular com-
ponent is autologous and has an internal vascular
network, will theoretically overcome the two major
hurdles in transplantation: the shortage of organs
and the toxicity deriving from lifelong immunosup-
pression.
This procedure is based on ex-vivo tissue
regeneration using a donor scaffold by repopulating
it with recipient-induced pluripotent stem cells
(iPSCs) or embryonic stem cells. Although a few
groups have been able to obtain a decellularized
kidney scaffold [17], the success in recellularizing
it has been rather scarce and limited to small vessels,
arterioles, and glomeruli being repopulated by
endothelial cells [18] and some tubular repopulation
[19]. The structural complexity of the kidney,
composed of more than 20 cell types, converts this
into a difficult endeavor compared with the partial
success obtained in heart, lung and liver [20,21].Mesenchymal stem cells
Mesenchymal stem cells are stromal cells that can
be found and isolated from virtually every tissue.
Because of interesting multilineage differentiation
potential and their ability to migrate to the site of
injury, they have been studied in the last 10 years
as a therapeutic agent in kidney injury. Although
initial studies observed migration of the injected
cells to injured kidney and even tubular replace-
ment [22], there is no solid evidence that those cells
can regenerate damaged tissue (by differentiation
or fusion) and truly give rise to kidney-specific cell
populations [23].
Although some studies have suggested that
about 2% of the injected MSCs engraft the injured
kidney [24], a recent study proved rapid clearancehorized reproduction of this article is prohibited.
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Organogenesis and organ regeneration and repair after transplantationof the injected cells that get trapped in the lungs
making impossible to detect any live injected cell
after 24h [25
&&
]. In that respect, to overcome the fast
clearance other injection routes (renal artery or
femoral artery) have been developed to increase
the chances of MSCs to get in touch with the kidney
[23,26]. However, even when MSCs are injected
systemically they exert a clear immunosuppressive
effect that can lead to long-term reduction of
interstitial fibrosis and tubular atrophy signs of
chronic kidney damage [27
&
]. This effect is partially
explained by the reduction in inflammatory
infiltrate that mediates tissue scarring, and also
by the ability of MSCs to shift the immuno-
logic balance toward a more anti-inflammatory
milieu (M2 macrophages, regulatory T cells,
tolerogenic dendritic cells) [28]. However, the anti-
inflammatory actions per se are generally not
sufficient to protect renal function and repair the
damaged organ.
Overall, the consensus about the regenerative
potential of MSCs is that they do not differentiate or
fuse into any kidney cell type, MSCs will only
reach the renal parenchyma when injected bypass-
ing the lungs, and that their mechanism of action is
through paracrine release of factors. Those factors
are also found in the conditioned media, which
when injected exert similar protective functions as
MSCs, and one of the most plausible mechanism
might be through released microvesicles.
Microvesicles
The use of MSC-derived microvesicles as a thera-
peutic agent to induce regeneration or at least to
reduce kidney rejection is a new approach that
evolved from the inconvenience of using whole
replicating cells and might be the mechanistic
explanation to solve the differential clearance/
effect observed with MSCs. Microvesicles are spon-
taneously released by many cell types including
MSCs, and they can present surface receptors and
contain biologically active proteins and lipids as
well as mRNA or microRNA. Therefore, they have
a potential role in the exchange of genetic material
between cells [29
&&
].
In addition to their immunomodulatory pro-
perties (same as MSCs), they showed potential to
activate proliferation in tubular epithelial cells in
glycerol-induced acute kidney injury combined
with severe combined immunodeficiency (SCID)
mice model [30]. This effect was comparable with
the one obtained with MSCs and was RNA depend-
ent. Similar effect was observed in a model of renal
ischemia/reperfusion injury, not only inhibiting
acute injury but also preventing the development
of chronic kidney disease [31].pyright © Lippincott Williams & Wilkins. Unautho
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As research in the field is growing, other therapies
and molecular mechanisms have been described
(Fig. 1).
Hepatocyte growth factor
Hepatocyte growth factor (HGF) has been broadly
studied because of its antifibrotic and pro-
regenerative properties in kidney damage models.
This short-lived growth factor presented some issues
in the administration as a protein and it soon
moved forward to an experimental gene therapy
application to provide sustained expression. This
has proved effective in acute ischemia/ reperfussion
injury [32] and in chronic kidney damage after
kidney transplantation [33]. One of the main
mechanisms of action was the shift in the balance
with TGFb inhibiting pro-scarring factors, and it
has been recently shown that when this therapy is
applied together with a hematopoietic stem cell
(HSC) mobilization factor (G-CSF), regeneration of
the injured kidney is enhanced by the migration
of bone-marrow-derivedM2macrophages to the site
of injury [34
&
].
This regenerative effect induced by the
migration of macrophages is in line with the effect
observed by Jung et al. [35
&
] of acute kidney
injury repair after injecting M2 macrophages over-
expressing IL-10.Microvasculature and pericytes
Chronic kidney disease is characterized by pro-
gressive loss of the renal microvasculature. Hence,
it is proposed that revascularization might be a key
process to restore kidney function and regenerate
the damaged structure. There are many therapeutic
approaches proposed to regenerate the micro-
vasculature, such as vascular endothelial growth
factor, angiopoietin-1 and endothelial progenitor
cells (reviewed in [36]), HSC [37], MSCs [38], and
the preservation of the pericytes.
Pericytes are cells of mesenchymal origin
that manage and coordinate endothelial action
and are also able to coordinate between endo-
thelium and epithelium [39]. In response to
injury, pericytes detach from the capillary walls
and migrate into the interstitium, where they are
activated contributing to fibrosis [40
&
]. This
detachment evidences the role of pericytes with
regard to microvasculature. In contrary, blocking
pericyte detachment not only results in a reduction
in interstitial fibrosis but also prevents capillary
rarefaction. Thus, strategies to modulate pericyte
function in these fibrotic processes are therefore
therapeutically attractive [41].rized reproduction of this article is prohibited.
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The kidney is a complex organ with a complex
structure that, in contrast with what was
believed, has the intrinsic capacity to regenerate.
New knowledge on progenitor cells within the
kidney, which in a steady state are responsible
for correct kidney repair, and on their use as a
therapeutic targets might be a key in the near future
to reduce fibrotic scarring or even induce regener-
ation. However, future research will tell us whether
these newly discovered progenitors are responsible
for the regeneration mediated by endogenous
signals or if they need external signaling (from
infiltrating cells) to start the regenerative process.
Regardless of the initial level of function, all
transplanted kidneys suffer some ischemia and
reperfusion injury followed by intrinsic regener-
ation. As biopsies are commonly obtained, the kid-
ney transplant could provide valuable information
about the regeneration of the human kidney.
Cell-based therapies are now being developed
with promising results. MSCs seem to play a role
in the reduction of damage, but their regenerative
role still needs to be proved whether it is only
a secondary effect to their immunoregulatory
properties. However, their regenerative potential
might be reduced because of their size after
culturing. This problem might be bypassed by local
injection of MSCs, the use of microvesicles, or new
strategies to come. Organ engineering of the kidney
is also moving fast and a full success in this field
could be the final solution to all the problems
related to organ transplantation. However, because
of the complexity of the kidney in structure and cell
types, a lot of research has to be done before we
reach that point.
Other therapies are also currently studied
among which we emphasize the use of HGF
and microvasculature repairing mechanisms. Both
represent important therapeutic approaches that
have shown interesting outcomes, although their
use might be in combination with other therapies.
Overall, kidney regeneration is a reality and the
knowledge of how to control it will be one of the
main scopes in the present and future.
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